However, PI3K pathway mutations in conjunction with KRAS G12C mutations in patients do not confer poorer survival outcomes in response to KRAS G12C inhibition in a large cohort of KRAS G12C-mutated NSCLC patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.